Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Lamivudine price, strengths & recalls

Pharmacies pay $14.40 for 30 tablets of Lamivudine 150 mg tablet this week, and from $14.40 to $272.28 across its 4 priced strengths and forms. 12 manufacturers make it. It is in shortage (being discontinued). It has 4 recalls on record, none ongoing. Its official label last changed on July 31, 2026.

Being discontinuedGeneric
Pharmacies pay$14.40for 30 tablets of 150 mg tablet-1.8% in 4 weeks
Fair cash price
$27.06
Strengths
4
Makers
12
Updated
Nov 11

Lamivudine price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
10 mg/mL oral solution$0.2176$52.23 / 240 mLNo change-6.1%
100 mg tablet$9.08$272.28 / 30 tablets-4.2%+4.6%
150 mg tablet$0.4801$14.40 / 30 tablets-1.8%+16.3%
300 mg tablet$1.42$42.64 / 30 tablets+1.4%+11.7%

The lowest cost per tablet is 150 mg tablet at $0.4801. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Supply status: shortages & recalls

In shortage2 products are short or being discontinued
No ongoing recalls4 recalls on record, latest Sep 18, 2019

Shortages

  • Epivir, Tablet, 300 mg (NDC 49702-204-13)ViiV Healthcare Company · Being discontinued Oct 19, 2026 · Updated Oct 19, 2026The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
  • Epivir, Tablet, 150 mg (NDC 49702-203-18)ViiV Healthcare Company · Being discontinued Oct 19, 2026 · Updated Oct 19, 2026The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for lamivudine? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedJuly 31, 2026
Version6 of 6
EffectiveJul 29, 2026
Read the label

These highlights do not include all the information needed to use LAMIVUDINE TABLETS (HBV) safely and effectively. See full prescribing information for LAMIVUDINE TABLETS (HBV). LAMIVUDINE tablets (HBV), for oral use Initial U.S. Approval: 1995

This drug has a boxed warning

WARNING: EXACERBATIONS OF HEPATITIS B and RISK OF HIV-1 RESISTANCE IF LAMIVUDINE TABLETS (HBV) IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1 INFECTION

Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy (including lamivudine tablets (HBV). Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted

[see

Warnings and Precautions (5.1)].

Lamivudine tablets (HBV) are not approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection because the lamivudine dosage in lamivudine tablets (HBV) is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 infection. HIV-1 resistance may emerge in chronic hepatitis B-infected patients with unrecognized or untreated HIV-1 infection. HIV counseling and testing should be offered to all patients before beginning treatment with lamivudine tablets (HBV) and periodically during treatment

[see

Warnings and Precautions (5.2)].

WARNING: EXACERBATIONS OF HEPATITIS B and RISK OF HIV-1 RESISTANCE IF LAMIVUDINE TABLETS (HBV) IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1 INFECTION

See full prescribing information for complete boxed warning

• Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy (including lamivudine tablets (HBV). Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment. (

5.1)

• Lamivudine tablets (HBV) contain a lower dose of the same active ingredient (lamivudine) as lamivudine tablets and oral solution used to treat human immunodeficiency virus type 1 (HIV-1) infection. HIV-1 resistance may emerge in chronic hepatitis B patients with unrecognized or untreated HIV-1 infection because the lamivudine dosage in lamivudine tablets (HBV) is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 infection. HIV counseling and testing should be offered to all patients before beginning treatment with lamivudine tablets (HBV) and periodically during treatment. (

5.2)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
8 approved generic applications on the market

Lamivudine questions

How much does lamivudine cost without insurance?

Pharmacies pay about $14.40 for 30 tablets of lamivudine 150 mg tablet ($0.4801 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $27.06. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is lamivudine in shortage?

Yes. 2 products are listed as in shortage or being discontinued (being discontinued). See which ones.

Has lamivudine been recalled?

4 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the lamivudine label last change?

The official label was last updated on July 31, 2026 (version 6). See what changed.

Talk about lamivudine

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.